LARGE-SCALE PRODUCTION & PURIFICATION OF COMPOUNDS WITH BIOLOGICAL ACTIVITY

生物技术股负责生产和纯化 生物材料。 该股进行了广泛的生物 生产任务，如原核细胞的大规模生长， 真核细胞，从微生物生产各种化合物， 真核细胞，特别是生物化合物的纯化 proteins.这些产品不能从商业来源获得， 用于临床和结构研究。 该单位有能力处理各种生产问题， 不同的主题 该股执行这项任务的方式是： 生理和技术手段。 有效的过程 开发和生产是可能的，因为该单位拥有 两个综合要素：全面运作的多用途试验生产 设施和进行研发的能力。 在过去的12个月里，该股进行了200次不同的大规模 准备工作 该股继续努力生产所需的大量蛋白质， 用于各种临床用途：来自牛视网膜的S抗原，目前 第二阶段的临床试验，和几个修改细菌 制备结合疫苗所需的蛋白毒素。 的 一个设施继续准备大量的各种哺乳动物细胞 开始一个生产阻断传播疫苗的项目 治疗疟疾

The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large-scale growth of procaryotic cells and eucaryotic cells, production of various compounds from microorganisms and eucaryotic cells, and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Unit is capable of handling various production problems associated with widely different topics. The Unit performs this task by implementing both physiological and technical approaches. Efficient process development and production is possible to perform since the Unit possesses two integrated elements: fully operational multi-purpose pilot production facility and the capability of conducting research and development. During the last 12 months the Unit performed 200 different large-scale preparations. The Unit continues its effort to produce large amounts of proteins needed for various clinical use: S antigen from bovine retina, currently in the second phase of the clinical trials, and several modified bacterial protein toxins needed for the preparation of conjugated vaccines. The facility continues to prepare large quantities of various mammalian cells and start a project for the production of a transmission-blocking vaccine for malaria.